Coeptis Therapeutics Holdings Inc
COEP11.270USD
+0.660+6.22%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
58.13MMarket Cap
LossP/E TTM
More Details of Coeptis Therapeutics Holdings Inc Company
Coeptis Therapeutics Holdings, Inc. is a biopharmaceutical and technology company. The Company is focused on developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Its product portfolio is highlighted by assets licensed from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. It is developing a universal, multi-antigen CAR technology licensed by the University of Pittsburgh (SNAP-CAR), and the GEAR cell therapy and companion diagnostic platforms in collaboration with VyGen-Bio and medical researchers at the Karolinska Institute. Its NexGenAI Affiliates Network platform offers AI-powered marketing software and robotic process automation capabilities. The Company’s subsidiaries include Coeptis Therapeutics, Inc., Coeptis Pharmaceuticals, Inc., GEAR Therapeutics, Inc. and SNAP Biosciences, Inc.
Coeptis Therapeutics Holdings Inc Info
Ticker SymbolCOEP
Company nameCoeptis Therapeutics Holdings Inc
IPO dateDec 17, 2020
CEOMehalick (David)
Number of employees5
Security typeOrdinary Share
Fiscal year-endDec 17
Address105 Bradford Road, Suite 420
CityWEXFORD
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code15090
Phone17249346467
Websitehttps://coeptistx.com/
Ticker SymbolCOEP
IPO dateDec 17, 2020
CEOMehalick (David)
Company Executives of Coeptis Therapeutics Holdings Inc
Name
Name/Position
Position
Shareholding
Change
Mr. David Mehalick
Mr. David Mehalick
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
130.07K
--
Ms. Christine Sheehy
Ms. Christine Sheehy
Vice President - Compliance, Secretary
Vice President - Compliance, Secretary
50.53K
--
Mr. Daniel (Dan) Yerace
Mr. Daniel (Dan) Yerace
Vice President - Operations, Director
Vice President - Operations, Director
45.53K
--
Mr. Christopher Calise
Mr. Christopher Calise
Independent Director
Independent Director
--
--
Mr. Brian Cogley
Mr. Brian Cogley
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Tara Maria Desilva, Ph.D.
Dr. Tara Maria Desilva, Ph.D.
Independent Director
Independent Director
--
--
Mr. Philippe Deschamps
Mr. Philippe Deschamps
Independent Director
Independent Director
--
--
Mr. Christopher Cochran
Mr. Christopher Cochran
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. David Mehalick
Mr. David Mehalick
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
130.07K
--
Ms. Christine Sheehy
Ms. Christine Sheehy
Vice President - Compliance, Secretary
Vice President - Compliance, Secretary
50.53K
--
Mr. Daniel (Dan) Yerace
Mr. Daniel (Dan) Yerace
Vice President - Operations, Director
Vice President - Operations, Director
45.53K
--
Mr. Christopher Calise
Mr. Christopher Calise
Independent Director
Independent Director
--
--
Mr. Brian Cogley
Mr. Brian Cogley
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Tara Maria Desilva, Ph.D.
Dr. Tara Maria Desilva, Ph.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Thu, Nov 20
Updated: Thu, Nov 20
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
5.89%
Calise (Chris)
5.43%
Mehalick (David)
2.26%
Armistice Capital LLC
1.64%
Sheehy (Christine Elise)
0.88%
Other
83.90%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
5.89%
Calise (Chris)
5.43%
Mehalick (David)
2.26%
Armistice Capital LLC
1.64%
Sheehy (Christine Elise)
0.88%
Other
83.90%
Shareholder Types
Shareholders
Proportion
Individual Investor
9.42%
Investment Advisor
6.11%
Hedge Fund
1.97%
Investment Advisor/Hedge Fund
1.13%
Other
81.37%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
36
241.64K
3.38%
--
2025Q3
37
241.64K
3.76%
+42.71K
2025Q2
35
198.94K
3.83%
+46.67K
2025Q1
35
152.27K
2.68%
+61.98K
2024Q4
37
107.84K
11.51%
-74.49K
2024Q3
50
182.34K
16.17%
+98.47K
2024Q2
52
83.87K
26.32%
-153.34K
2024Q1
74
237.20K
33.65%
-370.03K
2023Q4
75
236.65K
31.22%
+72.09K
2023Q3
78
164.55K
39.28%
-2.06K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
50.67K
0.89%
+23.15K
+84.08%
Sep 30, 2025
Calise (Chris)
312.69K
5.5%
--
--
Dec 18, 2025
Mehalick (David)
130.07K
2.29%
--
--
Dec 18, 2025
Armistice Capital LLC
94.77K
1.67%
+94.77K
--
Sep 30, 2024
Sheehy (Christine Elise)
50.53K
0.89%
--
--
Dec 18, 2025
Yerace (Daniel Alexander)
45.53K
0.8%
--
--
Dec 18, 2025
Geode Capital Management, L.L.C.
37.38K
0.66%
+17.10K
+84.30%
Sep 30, 2025
State Street Investment Management (US)
19.87K
0.35%
+19.87K
--
Sep 30, 2025
Renaissance Technologies LLC
18.50K
0.33%
+18.50K
--
Sep 30, 2025
Yorkville Advisors Global, LP.
8.00K
0.14%
-44.72K
-84.83%
Sep 30, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
Dec 27, 2024
Merger
20→1
Dec 27, 2024
Merger
20→1
Dec 27, 2024
Merger
20→1
Dec 27, 2024
Merger
20→1
Date
Ex-dividend Date
Type
Ratio
Dec 27, 2024
Merger
20→1
Dec 27, 2024
Merger
20→1
Dec 27, 2024
Merger
20→1
Dec 27, 2024
Merger
20→1
